Tassis Panagiotis, Pel Suzanne, Floros Dimitrios, Haar Kim Ter, Cao Qi, Tsakmakidis Ioannis, Papatsiros Vassileios, Ntarampa Niki, Arsenakis Ioannis, Tzika Eleni D
Farm Animals Clinic, School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
MSD Animal Health, Boxmeer, The Netherlands.
Porcine Health Manag. 2025 Apr 7;11(1):19. doi: 10.1186/s40813-025-00431-y.
Porcine circovirus 2 (PCV2) and Mycoplasma hyopneumoniae (M hyo) are two of the most important swine pathogens with variable clinical presence in swine farms globally, affecting health and performance of pigs under field conditions. The primary objective of this study was to assess the efficacy of a ready to use intradermal (ID) vaccine (Porcilis PCV M Hyo ID, MSD Animal Health, The Netherlands) against PCV2 associated disease and M hyo associated enzootic pneumonia under practical (field) conditions. In addition, the safety of the test product was clinically assessed, as the study animals were examined for general and local side effects after vaccination. A total of 678 animals in a Greek farrow to finish farm were equally divided in two trial groups (test and control group). Test group animals received the test vaccine at the age of three weeks, while control group animals remained unvaccinated. Parameters regarding health [lung lesion score (LLS) and pleurisy scoring, PCV2 viraemia and shedding] and performance [body weight (BW), average daily weight gain (ADWG)] were recorded and evaluated.
Vaccination improved the ADWG during both the finishing period (improvement by 34 g; p < 0.0001), and the overall period (increase by 24 g; p < 0.0001). Moreover, reduced mean LLS values (p < 0.0001), as well as reduced percentage of animals with pleurisy (p = 0.0082) and a decrease in PCV2 viraemia (p < 0.0001) and viral shedding (p = 0.0181) were observed in vaccinated animals when compared with the unvaccinated controls. As regards safety, a slight local skin reaction at the site of vaccination was detected and in two pigs a mild systemic reaction was reported with full recovery.
Findings suggested that the test vaccine is safe and effective against both PCV2 and M hyo associated diseases in vivo, thus it's use as part of a vaccination programme under field conditions is expected to improve respective health and performance parameters in pigs.
猪圆环病毒2型(PCV2)和猪肺炎支原体(M hyo)是全球养猪场中最重要的两种猪病原体,在猪场中临床表现各异,影响着猪场条件下猪的健康和生产性能。本研究的主要目的是评估一种即用型皮内(ID)疫苗(Porcilis PCV M Hyo ID,荷兰MSD动物保健公司)在实际(田间)条件下预防PCV2相关疾病和M hyo相关地方性肺炎的效果。此外,由于对研究动物接种疫苗后的全身和局部副作用进行了检查,因此对受试产品的安全性进行了临床评估。希腊一个从仔猪到育肥猪的猪场中的678只动物被平均分为两个试验组(试验组和对照组)。试验组动物在三周龄时接种受试疫苗,而对照组动物不接种疫苗。记录并评估了有关健康状况[肺部病变评分(LLS)和胸膜炎评分、PCV2病毒血症和排毒情况]和生产性能[体重(BW)、平均日增重(ADWG)]的参数。
接种疫苗在育肥期(增重34克;p<0.0001)和整个时期(增重24克;p<0.0001)均提高了ADWG。此外,与未接种疫苗的对照组相比,接种疫苗的动物的平均LLS值降低(p<0.0001),胸膜炎动物的百分比降低(p = 0.0082),PCV2病毒血症(p<0.)和病毒排毒情况也有所下降(p = 0.0181)。在安全性方面,在接种部位检测到轻微的局部皮肤反应,有两头猪报告出现轻度全身反应,但已完全恢复。
研究结果表明,受试疫苗在体内对PCV2和M hyo相关疾病均安全有效,因此在田间条件下作为疫苗接种计划的一部分使用有望改善猪的相应健康和生产性能参数。